ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.
Abstract
Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [7]
In the citing paper
“It is of particular interest that, contrary to other lipid-lowering drugs, such as PCSK9 inhibitors,21,22 the lipid lowering effect of ANGPTL3 inhibition by evinacumab seems to be independent of the presence of residual LDLR activity, supporting the data obtained in animal models,6,10 as well as in a pilot clinical trial.9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Based on the data collected during the parent clinical trials and other studies, LDL-C levels typically reach nadir after 4 weeks of receiving evinacumab infusion and remain generally stable at week 6.9”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationExome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Cited by
Items 201–300 of 329
Pu, X., Sale, M. E., Yang, F., Zhang, Y., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12711 · Cited by 10
Phenome-wide Mendelian randomization study of plasma triglyceride levels and 2600 disease traits
Park, J. K., Bafna, S., Forrest, I. S., Duffy, Á., Márquez‐Luna, C., Petrazzini, B. O., Vy, H. M. T., Jordan, D. M., Verbanck, M., Narula, J., et al. (2023) · eLife · doi:10.7554/elife.80560 · Cited by 11
“…targets have now been validated, including angiopoietin-like 3 (ANGPTL3) ( Graham et al., 2017 ; Dewey et al., 2017 ; Musunuru et al., 2010 ; Gaudet et al., 2017 ), angiopoietin-like 4 (ANGPTL4) ( Dewey et al., 2016 ), and apolipoprotein C-III (APOC3) ( Gaudet et al., 2015 ; Crosby et al.,…”
Page, M. M., Ekinci, E. I., Burnett, J. R., Hooper, A. J., Reid, N., Bishop, W., Florkowski, C. M., Scott, R. S., O’Brien, R. C., & Watts, G. F. (2020) · Journal of Clinical Apheresis · doi:10.1002/jca.21839 · Cited by 10
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
A New Insight on Atherosclerosis Mechanism and Lipid-Lowering Drugs
Li, P., & Jiang, W. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25321 · Cited by 8
“In patients with homozygous familial hypercholesterolemia, evinacumab can lower plasma LDL levels by 20% to 90% and triglyceride levels by 50% [103].”
Srivastava, R. A. K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.010 · Cited by 9
Rached, F. H., & Santos, R. D. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01514-2 · Cited by 9
Grassi, G. M., Pinto, R. D., Rosei, C. A., Agnoletti, D., Borghi, C., Cicero, A. F. G., Ciuceis, C. D., Desideri, G., Grassi, D., Muiesan, M. L., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00501-6 · Cited by 9
“In a phase 2 study of nine patients with homozygous familial hypercholesterolaemia, treatment with evinacumab resulted in an average 49% reduction in LDL cholesterol levels after 4 weeks from baseline [44].”
BackgroundTargeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 9
Khoury, É., Croteau, L., Lauzière, A., & Gaudet, D. (2022) · Future Cardiology · doi:10.2217/fca-2021-0149 · Cited by 8
Self-citationEvinacumab for Homozygous Familial Hypercholesterolemia
Luo, F., Das, A., & Fang, Z. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2033612 · Cited by 8
Inia, J. A., van Nieuwkoop, A., Jukema, J. W., Rolin, B., Staarup, E. M., Mogensen, C., Princen, H. M. G., & van den Hoek, A. M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100753 · Cited by 7
“The latter has been demonstrated to strongly improve plasma cholesterol and triglycerides in humans (15, 16) via a (different) mechanism that may act complementary to PCSK9 inhibition.”
Gu, J., Ma, X., Park, J.-N., Li, Y., & Sanchez, R. J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.004 · Cited by 7
Managing of dyslipidaemia characterized by accumulation of triglyceride-rich lipoproteins
Visser, J., van Zwol, W., & Kuivenhoven, J. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00979-y · Cited by 7
Preventing Premature Atherosclerotic Disease
Baker-Smith, C. M., & Peterson, A. L. H. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01097-3 · Cited by 8
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
“background lipid-lowering therapy further reduced LDL-C level by 49% [38].”
BackgroundNovel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 8
Ağırbaşlı, D., Hyatt, T., & Ağırbaşlı, M. A. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.008 · Cited by 7
Palmisano, B. T., Zhu, L., Litts, B., Burman, A., Yu, S., Neuman, J. C., Anozie, U., Luu, T. N., Edington, E. M., & Stafford, J. M. (2021) · Metabolites · doi:10.3390/metabo11050330 · Cited by 7
Advances in familial hypercholesterolemia
Paquette, M., & Baass, A. W. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.004 · Cited by 6
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia
Khoury, É., Brisson, D., & Gaudet, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1704728 · Cited by 6
Self-citationWhite, R. T., Sankey, K. H., & Nawarskas, J. J. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000522 · Cited by 6
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 10
“…lipase and metabolism of TRLs. Early studies have demonstrated that ANGPTL3 inhibition produces dose dependent lowering of triglycerides, particularly in the setting of familial chylomicronemia syndrome [91,92], and LDL cholesterol in patients with homozygous familial hypercholesterolemia [93].”
BackgroundPage, M. M., Bell, D. A., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13685 · Cited by 6
“Inhibition of ANGPTL3 mRNA transcripts by the use of an antisense oligonucleotide, or of the mature ANGPTL3 protein by a monoclonal antibody, shows promise in lowering LDL-cholesterol, including in patients with homozygous FH.(65,66)”
MethodThe Lifelong Burden of Homozygous Familial Hypercholesterolemia
Banerjee, A., Alothman, L., Couture, P., Bergeron, J., Bélanger, A. M., Ruel, I. L., & Genest, J. J. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.06.009 · Cited by 6
Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
Doggrell, S. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1862083 · Cited by 6
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0005 · Cited by 6
“The mean reduction in triglyceride, LDL, HDL, non-HDL, and apo B level at 4 weeks was 47%, 49%, 36%, 49%, and 46%, respectively [31].”
BackgroundMethodIdentifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3
Blackburn, N. B., Meikle, P. J., Peralta, J. M., Kumar, S., Leandro, A. C., Bellinger, M. A., Giles, C., Huynh, K., Mahaney, M. C., Göring, H. H. H., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003232 · Cited by 6
Lipoprotein and Lipid Metabolism
Hegele, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00007-8 · Cited by 8
Qureshi, Z. A., Khanzada, M., Safi, A., Fatima, E., Altaf, F., & Vittorio, T. J. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001945 · Cited by 6
Cicero, A. F. G., Mahjoubin-Tehran, M., Reiner, Ž., Eid, A. H., Jamialahmadi, T., & Sahebkar, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100110 · Cited by 5
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Self-citationAntisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
Ogieuhi, I. J., Callender, K., Odukudu, G.-D. O., Obi, E. S., Muzofa, K., Babalola, A. E., Ugiomoh, O. M.-A., Umenzeakor, K. H., Akingbola, A., Ayoson, C. O., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00682-w · Cited by 5
Maternal Serum Angiopoietin-Like 3 Levels in Healthy and Mild Preeclamptic Pregnant Women
Garcés, M. F., Rodríguez‐Navarro, H. A., Buell‐Acosta, J. D., Burgos-Cárdenas, Á. J., Vega, R. F., Acosta, L. M. M. , Schmalbach, J. E., Baños, A. J. P., Pinzón, A. C. , Sánchez, E., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.670357 · Cited by 5
“Furthermore, it was recently shown that the monoclonal antibody, Evinacumab, an ANGPTL3 inhibitor, reduced triglycerides in healthy human volunteers and in homozygous familial hypercholesterolemic individuals (26, 27).”
BackgroundAn update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Self-citationHypertriglyceridemia as a multidisciplinary problem of modern medicine
Васильевна, Ц. О., Ozhiganova, N. V., Kastalap, V. V., Саяровна, Б. С., & Latyntseva, L. D. (2020) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2020-9-4-114-123 · Cited by 6
“Основной конечной точкой работы являлась оценка снижения уровня ЛНП в течение четырех недель приема эвинакумаба [24].”
Zhang, Y.-J., Zhang, L., Feng, F., & Cao, Q. (2021) · Disease Markers · doi:10.1155/2021/2863856 · Cited by 10
Wang, D., Feng, D., Wang, Y., Dong, P., Wang, Y., Zhong, L., Li, B., Fu, J., Xiao, X., Speakman, J. R., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.788549 · Cited by 7
“Prior clinical study has found that antibodiesinduced ANGPTL3 inhibition resulted in substantial reductions in LDL-C levels in patients (48), and in mice”
BackgroundANGPTL3 targeting: The power of versatile lipid-lowering
Pessentheiner, A. R., Ramms, B., & Gordts, P. L. S. M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.002 · Cited by 5
Obeng, E., Ergashev, A., Yao, Q., Wu, W., & Chen, G. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s514653 · Cited by 4
Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia
Rosenson, R. S., Brinton, E. A., Gaudet, D., Raal, F. J., Baker-Smith, C. M., Moriarty, P. M., Greber‐Platzer, S., Bergeron, J., McCrindle, B. W., Waldron, A., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120627 · Cited by 7
Self-citationAngiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias
Kosmas, C. E., Rallidis, L. S., Hoursalas, I. S., Papakonstantinou, E. J., & Kostara, C. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020921 · Cited by 4
“According to the authors, all nine patients reported the occurrence of at least one adverse event, but no event led to treatment discontinuation [29].”
Larouche, M., Banerjee, P., Brisson, D., Pordy, R. C., & Gaudet, D. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf025 · Cited by 4
“1A) [14-16].”
Self-citationUpdate on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Ossoli, A., Minicocci, I., Turri, M., Costanzo, A. D., D’Erasmo, L., Bini, S., Montavoci, L., Veglia, F., Calabresi, L., & Arca, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159263 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
“The study was completed with 9 hoFH patients [102].”
BackgroundPedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.12.001 · Cited by 7
Bicciato, G., Arnold, M., Gebhardt, A., & Mira, K. (2021) · Current Opinion in Neurology · doi:10.5167/uzh-210372 · Cited by 7
White, O., Aligabi, Z., Burks, K. H., Tang, J., Stitziel, N. O., Goldberg, I. J., Remaley, A. T., & Lucero, D. (2025) · doi:10.1101/2025.03.02.640965 · Cited by 4
Further options for treating lipids in people with diabetes: targeting LDL ‐cholesterol and beyond
Wierzbicki, A. S. (2018) · Diabetic Medicine · doi:10.1111/dme.13667 · Cited by 5
New Biotechnological Treatments for Lipid Disorders
Valencia‐Enciso, N., & Mendivil, C. O. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002577 · Cited by 3
Homozygous familial hypercholesterolemia and its treatment by inclisiran
Marais, A. D., Blom, D. J., & Raal, F. J. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1784721 · Cited by 3
Pek, S. L. T., Yap, F. K. P., Sreedharan, A. V., Choo, J. T. L., & Tavintharan, S. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.04.008 · Cited by 3
Circulating Levels of PCSK9, ANGPTL3 and Lp(a) in Stage III Breast Cancers
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.007 · Cited by 4
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 4
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups
Wu, N., Li, Z.-F., Lu, M.-Y., & Li, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2321374 · Cited by 4
“It can effectively reduce LDL-C levels even in homozygous FH (HoFH) patients with null LDLR mutations, owing to its LDLR-independent mechanism [25–27].”
BackgroundOlatunji, G. D., Kokori, E., Moradeyo, A. A., Lema, K. F., Ayo, O. R., Obasanjo, O. M., Mustapha, M. J., Stanley, A. C., & Aderinto, N. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00335-3 · Cited by 3
“Gaudet et al.’s (2017) open-label study involving nine adults offers insights into real-world applications [21].”
BackgroundANGPTL3 and ANGPTL8 in Thai subjects with hyperalphalipoproteinemia and severe hypertriglyceridemia
Kaewkrasaesin, C., Chatchomchuan, W., Muanpetch, S., & Khovidhunkit, W. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.059 · Cited by 3
Familial hypercholesterolaemia: New directions on the diagnosis and treatment of an old disease
Rallidis, L. S., & Kosmas, N. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.06.014 · Cited by 3
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Singh, L., Gašić, V., Komazec, J., Grubiša, I., Popović, L., Rasulić, I., Petakov, A., Mitrović, M., Mihailović, E., Pavlović, S., et al. (2025) · Journal of Medical Biochemistry · doi:10.5937/jomb0-62224 · Cited by 2
“Moreover, ANGPTL3 inhibition (e.g., evinacumab) effectively reduces TG and LDL-C in FH and severe dyslipidemia, reinforcing the therapeutic relevance of this pathway (39-41).”
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes
Wahab, R. A., & Mahmood, W. A. W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261422310 · Cited by 2
“92,93 Adverse events that need to be considered include hepato-toxicity, injection site reaction, hepatic fat accumulation, and high cost.”
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
“…maximally tolerated lipid-lowering therapy, evinacumab (250 mg subcutaneous followed by 15 mg/kg IV at 2 weeks) reduced LDL-C, apoB, non-HDL-C, TG, and HDL-C by 49%, 46%, 49%, 47%, and 36%, respectively, at week 4, with no treatment interruptions due to adverse events (Gaudet et al., 2017).”
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Муратович, Н. А., & Витальевна, К. К. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x305291240715112812 · Cited by 2
ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states
Nagai, T. H., Mizoguchi, T., Wang, Y., Deik, A., Bullock, K. H., Clish, C. B., & Xu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-89552-6 · Cited by 2
Corpataux, N., Aregger, F., Koskinas, K. C., & Gebhard, C. (2025) · Swiss Medical Weekly · doi:10.57187/s.4024 · Cited by 2
Bihorel, S., Dingman, R. K., Mendell, J., Wang, Y., Banerjee, P., Pordy, R. C., Davis, J. D., DiCioccio, A. T., & Harnisch, L. O. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70016 · Cited by 4
Self-citationTran, H. H.-V., Thu, A., Twayana, A. R., Fuertes, A., Gonzalez, M., Basta, M., James, M., Mahadevaiah, A., Mehta, K. A., Islek, D., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000976 · Cited by 3
Toroghi, M. K., Bosley, J., Powell, L. M., Zhang, Y., Yang, F., Pu, X., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12694 · Cited by 2
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 3
Hypertriglyceridaemia in adolescents may have serious complications
Korf, M., Zöllner, E. W., Solomon, G. A. E., Zemlin, A. E., & Marais, A. D. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i5.16387 · Cited by 2
“The experience with these two cases with severe metabolic derangements highlights the problem of the diagnosis and management of metabolic disorders in SA.”
BackgroundInfluentialGaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Self-citationLotta, L. A., Dong, L., Li, C., Patel, S., Stewart, I. D., Lim, K., Day, F. R., Wheeler, E., Glastonbury, C. A., de Streek, M. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372128 · Cited by 2
Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia
Duell, P. B., & Fazio, S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.001 · Cited by 2
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Atherosclerosis and inflammation: therapeutic targets and ways of correction
Клименко, А. А., Andriyashkina, D. Y., & Ogarkova, K. I. (2024) · The Clinician · doi:10.17650/1818-8338-2024-18-1-k696 · Cited by 2
TransferTWAS: A transfer learning framework for cross-tissue transcriptome-wide association study
Lai, D., Wang, H., Gu, T., Wu, S., Liu, D. J., Sham, P. C., & Zhang, Y. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.06.006 · Cited by 2
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Brisson, D., Wiegman, A., Waldron, A., Kainth, P., Raal, F. J., & Gaudet, D. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101395 · Cited by 2
“They were either evinacumab naïve ( n = 46) or had previously received evinacumab during their participation in the phase 2 proof-of-concept study (NCT02265952) or the phase 3 ELIPSE-HoFH study (NCT03399786) ( n = 70) [8,9].”
InfluentialSelf-citationDyslipidemias in Chronic Kidney Disease: Pathophysiology and Emerging Therapies
Capón, I. M., Lerma, E. V., Anandh, U., So, P. N., & Hassanein, M. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_711_2025 · Cited by 1
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 2
“A phase 2 study in 9 HoFH patients taking aggressive lipid-lowering therapy, showed that evinacumab reduced LDL-C by a mean of 49% irrespective of the type of mutation in the LDLR [142,143].”
Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease
Srivastava, S. P., Arora, A., Hamed, M., Urval, A., Dupati, A., Xia, S., Yoshida, S., & Inoki, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1803412 · Cited by 1
Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels
Hegele, R. A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671686 · Cited by 2
“Evinacumab, a fully human monoclonal antibody that binds circulating ANGPTL3, provided the first clinical proof-of-concept for therapeutic ANGPTL3 inhibition [22,23].”
InfluentialGenetic Disorders of Lipoprotein Metabolism
Brown, A. S., Dababneh, E. G., Chaus, A. M., Chyzhyk, V., Marinescu, V., & Pyslar, N. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_3 · Cited by 2
Genetic disorders of lipoprotein metabolism
Bhatnagar, D., Schofield, J. D., & Soran, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809356-6.00014-9 · Cited by 3
Sreedharan, A. V., Pek, S. L. T., Tan, T. H., Subramaniam, T., & Yap, F. K. P. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.07.006 · Cited by 1
Bao, J., Liu, S., Liang, X., Wang, C., Cao, L., Li, Z., Wei, F., Fu, A. L., Shi, Y., Shen, B., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202201576 · Cited by 2
“The predictor ANGL3 obtained among 1,517 proteins is a specific secreted protein originally expressed in the liver, enhancing expression of plasma cholesterol (Gaudet et al, 2017).”
BackgroundHypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Hypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
Vogt, A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-4373-0 · Cited by 1
Commentary on rare dyslipidaemia paper
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.012 · Cited by 1
Future Energy Supply, Simulations with Limited Resources
Benichou, L. (2011) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia
Ajufo, E., & Cuchel, M. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1394841
“In a proof-ofconcept study in HoFH subjects, a multiple-dosing schedule of REGN1500 lowered LDL-C concentration by a mean of ~ 50% in patients on optimum lipid-lowering therapy including lomitapide and PCSK9 inhibitors [88].”
BackgroundSelf-citationHomozygous familial hypercholesterolaemia: New hope for getting patients to goal?
Stock, J. K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.016
Management of Homozygous Familial Hypercholesterolemia
Santos, R. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_20
iPSCs for modeling familial hypercholesterolemia type II A
Caron, J., Dubart‐Kupperschmitt, A., & Weber, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-822227-0.00010-7
Metadata
- Authors
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl, N., Yancopoulos, G. D., & Hovingh, G. K.
- Affiliations
- Université de Montréal (CA)
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pennsylvania (US)
- Cedars-Sinai Medical Center (US)
- University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 296-297
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2738009647
- Cited by
- 323
- References
- 5
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 29 · 2023: 23 · 2022: 41 · 2021: 58 · 2020: 62 · 2019: 36 · 2018: 30 · 2017: 4
- FWCI
- 36.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, evinacumab, homozygous familial hypercholesterolemia, LDL cholesterol lowering, monoclonal antibodies, cholesterol absorption inhibition, lipid-lowering therapy
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Antibodies, Monoclonal, Genotype, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Receptors, LDL, Angiopoietins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.